19-Mar-2020 | Facts and Factors
The global Florbetapir market in 2019 was approximately USD 69 Million. The market is expected to grow at a CAGR of 3.6% and is anticipated to reach around USD 89 Million by 2026.
Florbetapir is also known as florbetapir-fluorine-18 and is the trade name Amyvid. For the florbetapir F 18 injection, Avid and Lilly Received FDA’s complete response letter in March 2011. FDA approved Amyvid for its application in patients evaluated with cognitive decline especially Alzheimer's disease in April 2012. However, the EU Commission permitted the drug to use commercially in 2013.
Browse the full “Florbetapir Market By Type (30 mL Vial and 50 mL Vial) and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/florbetapir-market-by-type-30-ml-vial-and-828
The article is selected for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque concentration in the brain of grown-up patients with a subjective disability who are being assessed for causes of cognitive impairment. A positive Amyvid scan indicates the significant presence of amyloid plaques. The product has been strictly included in intravenous administration and is approved for only diagnostic use.
The rising prevalence of dementia is the chief reason behind the development of the florbetapir molecule. Dementia refers to a group of symptoms that comprises a failure in the ability to relate to others, reason, think, and remember. The symptoms can get worse over time until the person can no longer live independently and take care of themselves. Dementia has a social, physical, economic, and psychological impact on patients with dementia as well as on their families and society at large.
Robust research and development activities and investment in clinical trials are anticipated to fuel the product demand over the forecast period. Furthermore, major drivers fueling the growth of the market include the growing geriatric population and increasing per capita healthcare expenditure. Regulations for manufacturing and clinical trials are some of the key factors hindering the growth of the florbetapir market across the globe especially in the U.S. Some of the key trending factors of the global florbetapir market are increasing focus on a primary diagnosis of cognitive impairment diseases and rising prevalence of dementia.
Over the past few years, healthcare spending has increased significantly across the globe owing to enhanced purchasing power, preference for high-standard healthcare facilities and processes with growing awareness about early diagnosis and prevention.
The North American region accounted for 53% market share of total revenue generated in 2019. Alzheimer’s disease (AD) is the most common form of dementia in the U.S. which is estimated to affect 5.5 million individuals. As per Alzheimer’s Association, there are about 5.8 million people with the disease, and that this figure is set to rise to almost 14 million by 2050; additionally, it is the sixth principal reason for death.
5.4 million people in the EU currently have dementia and one in every 20 people over the age of 65 have AD, the most common form of dementia. Some of the projects include The European Prevention of Alzheimer’s Dementia (EPAD), Interdisciplinary Network for Dementia Utilizing Current Technology (INDUCT), and Amyloid imaging to prevent Alzheimer’s disease. According to the World Alzheimer Report 2010, costs associated with dementia for the Asia Pacific region have been estimated at USD 185 Billion. Around 70% of the total costs of dementia care were from advanced economies, which contain 18% of the prevalence. The Asia Pacific countries already have around half of the world’s population and the number of people living with dementia in the region will triple between now and 2050. There is an urgent need for governments to put in place policies and plans to ensure that adequate care and services are provided to people living with dementia in the future.
According to the World Alzheimer Report, in Latin America, the number of people with dementia is predicted to increase four-fold from 2015 to 2050. The World Health Organization stated 5.5% to 7% dementia prevalence with a standardized prevalence of 8.5%, although several Latin American countries are underrepresented in these statistics, and dementia prevalence may be underestimated.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 69 Million |
Projected Market Size in 2026 |
USD 89 Million |
CAGR Growth Rate |
3.6% CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Eli Lilly, Navidea Biopharmaceuticals, Piramal Healthcare, GE Healthcare, and others. |
Key Segment |
By Type, By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
This report segments the Florbetapir market as follows:
Global Florbetapir Market: By Type Segmentation Analysis
Global Florbetapir Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of the Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
